Skip to main content
Contact Us
Subscribe
E-Edition
54°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
160.88
+0.03 (+0.02%)
Streaming Delayed Price
Updated: 3:56 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
November 26, 2024
Via
The Motley Fool
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
November 20, 2024
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
Via
Benzinga
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
November 18, 2024
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.
Via
Benzinga
This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
November 18, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Biogen Through Analyst Insights
November 14, 2024
Via
Benzinga
Evaluating Biogen: Insights From 17 Financial Analysts
November 04, 2024
Via
Benzinga
Biogen Analysts Slash Their Forecasts After Q3 Results
October 31, 2024
Via
Benzinga
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
November 15, 2024
Via
Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
October 31, 2024
Via
Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
October 30, 2024
The biotech giant also raised full-year EPS guidance.
Via
Investor's Business Daily
Looking Into Biogen's Recent Short Interest
October 22, 2024
Via
Benzinga
The Latest Analyst Ratings For Biogen
October 10, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Biogen (BIIB) Q3 2024 Earnings Call Transcript
October 30, 2024
BIIB earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
October 30, 2024
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance.
Via
Benzinga
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
October 23, 2024
Fewer contenders means fewer constraints on expanding market share.
Via
The Motley Fool
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
October 17, 2024
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and...
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Looking Into Biogen's Recent Short Interest
October 03, 2024
Via
Benzinga
Forecasting The Future: 20 Analyst Projections For Biogen
September 23, 2024
Via
Benzinga
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
October 16, 2024
Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans...
Via
Benzinga
Exposures
Product Safety
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
October 14, 2024
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns.
Via
Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 13
October 13, 2024
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.
Via
Talk Markets
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
October 08, 2024
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Via
Benzinga
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
October 07, 2024
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...
Via
Benzinga
Exposures
Product Safety
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
September 28, 2024
It's hard to bet against this company right now.
Via
The Motley Fool
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
September 26, 2024
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...
Via
Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
September 24, 2024
UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48...
Via
Benzinga
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
September 09, 2024
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.